Literature DB >> 21354372

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Ivana Bozovic-Spasojevic1, Hatem A Azim, Marianne Paesmans, Thomas Suter, Martine J Piccart, Evandro de Azambuja.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21354372     DOI： 10.1016/S1470-2045(11)70013-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.

Authors:  Feng Du; Peng Yuan; Wenjie Zhu; Jiayu Wang; Fei Ma; Ying Fan; Binghe Xu
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

Review 3.  Targeted therapies in breast cancer: are heart and vessels also being targeted?

Authors:  Carmen Criscitiello; Otto Metzger-Filho; Kamal S Saini; Gilberto de Castro; Marie Diaz; André La Gerche; Evandro de Azambuja; Martine J Piccart-Gebhart
Journal:  Breast Cancer Res       Date:  2012-06-19       Impact factor: 6.466

Review 4.  Twenty years of anti-HER2 therapy-associated cardiotoxicity.

Authors:  Noam F Pondé; Matteo Lambertini; Evandro de Azambuja
Journal:  ESMO Open       Date:  2016-07-21

5.  Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans.

Authors:  Philip Carter; Costi Alifrangis; Biancastella Cereser; Pramodh Chandrasinghe; Lisa Del Bel Belluz; Nina Moderau; Fotini Poyia; Lee S Schwartzberg; Neha Tabassum; Jinrui Wen; Jonathan Krell; Justin Stebbing
Journal:  Oncotarget       Date:  2018-02-24

6.  Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials.

Authors:  Yu-Tuan Wu; Zhou Xu; Bilal Arshad; Jiu-Song Wu; Ke Zhang; He Wu; Xin Li; Hao Li; Ying-Cun Li; Zhong-Liang Wang; Kai-Nan Wu; Ling-Quan Kong
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.